Development & Clinical Application of K-PaC Registry Version 2.0

NCT07171515 | Enrolling By Invitation

• 1 other identifier: NCC2022-0061
• Study Type: observational
• Target: 6,923
• Locations: 1 country
• Sites: 1

Brief Summary

Development and clinical use of pancreatic cancer registry

• Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029
• Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

• Development and clinical use of a pancreatic cancer registry

  Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

  From initial diagnosis to death

Secondary Outcomes (1)

• Assessing the association between pancreatic cancer biomarker markers and treatment response, overall and progression-free survival

  From initial diagnosis to death

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

pancreatic cancer

You may qualify if:

• Clinical diagnosis of pancreatic cancer

You may not qualify if:

• In cases where medical record review is not feasible

Sponsors & Collaborators

• National Cancer Center, Korea: lead

Study Sites (1)

National Cancer Center

Goyang, Gyeonggido, 10408, South Korea

Location

Related Links

• 1\. Guidelines for the Pancreatic Cancer Registry, National Cancer Center Big Data Center
• 2\. CONNECT Cancer Big Data Library: Pancreatic Cancer Section
• Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches

Biospecimen

Retention: SAMPLES WITH DNA

Transcriptome, Whole genome, Epigenome, Proteome, Metabolome

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 1 Year
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head, Center for Liver and Pancreatobiliary Cancer

Study Record Dates

• First Submitted: June 15, 2025
• First Posted: September 12, 2025
• Study Start: January 2, 2023
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2030
• Last Updated: September 12, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)